Journal: Experimental and Therapeutic Medicine

Article Title: miR-126-5p regulates H9c2 cell proliferation and apoptosis under hypoxic conditions by targeting IL-17A

doi: 10.3892/etm.2020.9499

Figure Lengend Snippet: miR-126-5p expression is downregulated and IL-17A is upregulated in serum samples obtained from patients with AMI and H9c2 cells following hypoxic treatment. (A) miR-126-5p and (B) IL-17A expression in patients with AMI and healthy individuals. IL-17A protein expression levels in the serum of patients with AMI and healthy individuals were (C) determined by western blotting and (D) quantified. (E) miR-126-5p and (F) IL-17A expression levels in H9c2 cells following hypoxic treatment. **P<0.01. miR, microRNA; IL, interleukin; control, healthy volunteers; AMI, acute myocardial infarction; hypoxic, H9c2 cells following hypoxic treatment; control, H9c2 cells.

Article Snippet: Subsequently, 2x10 4 cells/well H9c2 cells were co-transfected with 40 nM wild-type or mutant IL-17A 3'UTR plasmids (Guangzhou RiboBio Co., Ltd.) and miR-126-5p mimics or NCs using Lipofectamine ® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.).

Techniques: Expressing, Western Blot

Journal: Experimental and Therapeutic Medicine

Article Title: miR-126-5p regulates H9c2 cell proliferation and apoptosis under hypoxic conditions by targeting IL-17A

doi: 10.3892/etm.2020.9499

Figure Lengend Snippet: IL-17A is a target of miR-126-5p. (A) The binding site between miR-126-5p and IL-17A was predicted using TargetScan. (B) Dual-luciferase reporter assay results. **P<0.01. IL, interleukin; miR, microRNA; NC, negative control; WT, wild-type; UTR, untranslated region.

Article Snippet: Subsequently, 2x10 4 cells/well H9c2 cells were co-transfected with 40 nM wild-type or mutant IL-17A 3'UTR plasmids (Guangzhou RiboBio Co., Ltd.) and miR-126-5p mimics or NCs using Lipofectamine ® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.).

Techniques: Binding Assay, Luciferase, Reporter Assay, Negative Control

Journal: Experimental and Therapeutic Medicine

Article Title: miR-126-5p regulates H9c2 cell proliferation and apoptosis under hypoxic conditions by targeting IL-17A

doi: 10.3892/etm.2020.9499

Figure Lengend Snippet: Transfection efficiency of miR-126-5p and IL-17A. (A) miR-126-5p expression following transfection with NC or miR-126-5p mimics. IL-17A (B) mRNA and (C) protein expression levels following transfection with pcDNA3.1 or pcDNA3.1-IL-17A. (D) miR-126-5p and (E) IL-17A expression following co-transfection with miR-126-5p mimics and pcDNA3.1-IL-17A. *P<0.05 and **P<0.01. miR, microRNA; IL, interleukin; NC, negative control; IL-17A, cells transfected with pcDNA3.1-IL-17A vector.

Article Snippet: Subsequently, 2x10 4 cells/well H9c2 cells were co-transfected with 40 nM wild-type or mutant IL-17A 3'UTR plasmids (Guangzhou RiboBio Co., Ltd.) and miR-126-5p mimics or NCs using Lipofectamine ® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.).

Techniques: Transfection, Expressing, Cotransfection, Negative Control, Plasmid Preparation

Journal: Experimental and Therapeutic Medicine

Article Title: miR-126-5p regulates H9c2 cell proliferation and apoptosis under hypoxic conditions by targeting IL-17A

doi: 10.3892/etm.2020.9499

Figure Lengend Snippet: miR-126-5p overexpression enhances H9c2 cell survival under hypoxic conditions. #P<0.01, mimics vs. NC group; **P<0.01, mimic + IL-17A vs. mimics group. miR, microRNA; NC, negative control; mimics + IL-17A, cells transfected with miR-126-5p mimics and pcDNA3.1-IL-17A vector; IL, interleukin.

Article Snippet: Subsequently, 2x10 4 cells/well H9c2 cells were co-transfected with 40 nM wild-type or mutant IL-17A 3'UTR plasmids (Guangzhou RiboBio Co., Ltd.) and miR-126-5p mimics or NCs using Lipofectamine ® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.).

Techniques: Over Expression, Negative Control, Transfection, Plasmid Preparation

Journal: Experimental and Therapeutic Medicine

Article Title: miR-126-5p regulates H9c2 cell proliferation and apoptosis under hypoxic conditions by targeting IL-17A

doi: 10.3892/etm.2020.9499

Figure Lengend Snippet: miR-126-5p overexpression suppresses H9c2 cell apoptosis under hypoxic conditions. Representative scatter plots for the (A) control, (B) NC, (C) mimics and (D) mimics + IL-17A groups. (E) Quantification of H9c2 cell apoptosis. **P<0.01. miR, microRNA; NC, negative control; mimics + IL-17A, cells transfected with miR-126-5p mimics and pcDNA3.1-IL-17A vector; IL, interleukin.

Article Snippet: Subsequently, 2x10 4 cells/well H9c2 cells were co-transfected with 40 nM wild-type or mutant IL-17A 3'UTR plasmids (Guangzhou RiboBio Co., Ltd.) and miR-126-5p mimics or NCs using Lipofectamine ® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.).

Techniques: Over Expression, Negative Control, Transfection, Plasmid Preparation

Journal: Experimental and Therapeutic Medicine

Article Title: miR-126-5p regulates H9c2 cell proliferation and apoptosis under hypoxic conditions by targeting IL-17A

doi: 10.3892/etm.2020.9499

Figure Lengend Snippet: miR-126-5p regulates H9c2 cell apoptosis via the PI3K/AKT signaling pathway. Protein expression levels were (A) determined by western blotting and (B) semi-quantified. *P<0.01 and **P<0.05. miR, microRNA; NC, negative control; mimics + IL-17A, cells transfected with miR-126-5p mimics and pcDNA3.1-IL-17A vector; p, phosphorylated; IL, interleukin.

Article Snippet: Subsequently, 2x10 4 cells/well H9c2 cells were co-transfected with 40 nM wild-type or mutant IL-17A 3'UTR plasmids (Guangzhou RiboBio Co., Ltd.) and miR-126-5p mimics or NCs using Lipofectamine ® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.).

Techniques: Expressing, Western Blot, Negative Control, Transfection, Plasmid Preparation